These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 18248814)

  • 1. Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway.
    Stauffer F; Maira SM; Furet P; García-Echeverría C
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1027-30. PubMed ID: 18248814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of novel furoquinoline based inhibitors of multiple targets in the PI3K/Akt-mTOR pathway.
    Lohar MV; Mundada R; Bhonde M; Padgaonkar A; Deore V; Yewalkar N; Bhatia D; Rathos M; Joshi K; Vishwakarma RA; Kumar S
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3603-6. PubMed ID: 18501601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential antitumor agents. 37. Synthesis and antitumor activity of guanylhydrazones from imidazo[2,1-b]thiazoles and from the new heterocyclic system thiazolo[2',3':2,3]imidazo[4,5-c]quinoline.
    Andreani A; Granaiola M; Leoni A; Locatelli A; Morigi R; Rambaldi M; Lenaz G; Fato R; Bergamini C; Farruggia G
    J Med Chem; 2005 Apr; 48(8):3085-9. PubMed ID: 15828848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors.
    Porta C; Figlin RA
    J Urol; 2009 Dec; 182(6):2569-77. PubMed ID: 19836781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
    Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
    Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug discovery approaches targeting the PI3K/Akt pathway in cancer.
    Garcia-Echeverria C; Sellers WR
    Oncogene; 2008 Sep; 27(41):5511-26. PubMed ID: 18794885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and anti-cancer activity of 1,4-disubstituted imidazo[4,5-c]quinolines.
    Thigulla Y; Akula M; Trivedi P; Ghosh B; Jha M; Bhattacharya A
    Org Biomol Chem; 2016 Jan; 14(3):876-83. PubMed ID: 26592542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and structure-activity relationship of 8-hydroxy-quinoline-7-carboxylic acid derivatives as inhibitors of Pim-1 kinase.
    Sliman F; Blairvacq M; Durieu E; Meijer L; Rodrigo J; Desmaële D
    Bioorg Med Chem Lett; 2010 May; 20(9):2801-5. PubMed ID: 20363627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential roles of phosphatidylinositol 3-kinase/akt pathway in retinal ganglion cell survival in rats with or without acute ocular hypertension.
    Huang Y; Cen LP; Luo JM; Wang N; Zhang MZ; van Rooijen N; Pang CP; Cui Q
    Neuroscience; 2008 Apr; 153(1):214-25. PubMed ID: 18358617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors.
    Woods KW; Fischer JP; Claiborne A; Li T; Thomas SA; Zhu GD; Diebold RB; Liu X; Shi Y; Klinghofer V; Han EK; Guan R; Magnone SR; Johnson EF; Bouska JJ; Olson AM; de Jong R; Oltersdorf T; Luo Y; Rosenberg SH; Giranda VL; Li Q
    Bioorg Med Chem; 2006 Oct; 14(20):6832-46. PubMed ID: 16843670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and cytotoxicity of 2-methyl-1-substituted-imidazo [4,5-g]quinoline-4,9-dione and 7,8-dihydro-10H-[1,4]oxazino[3',4':2,3]imidazo[4,5-g]quinoline-5,12-dio ne derivatives.
    Suh ME; Kang MJ; Yoo HW; Park SY; Lee CO
    Bioorg Med Chem; 2000 Aug; 8(8):2079-83. PubMed ID: 11003153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors.
    Hayakawa M; Kawaguchi K; Kaizawa H; Koizumi T; Ohishi T; Yamano M; Okada M; Ohta M; Tsukamoto S; Raynaud FI; Parker P; Workman P; Waterfield MD
    Bioorg Med Chem; 2007 Sep; 15(17):5837-44. PubMed ID: 17601739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery and structure-activity relationships of a series of quinoline and quinoxaline derivatives.
    Nishimura N; Siegmund A; Liu L; Yang K; Bryan MC; Andrews KL; Bo Y; Booker SK; Caenepeel S; Freeman D; Liao H; McCarter J; Mullady EL; San Miguel T; Subramanian R; Tamayo N; Wang L; Whittington DA; Zalameda L; Zhang N; Hughes PE; Norman MH
    J Med Chem; 2011 Jul; 54(13):4735-51. PubMed ID: 21612232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3K/Akt inhibition modulates multidrug resistance and activates NF-kappaB in murine lymphoma cell lines.
    García MG; Alaniz LD; Cordo Russo RI; Alvarez E; Hajos SE
    Leuk Res; 2009 Feb; 33(2):288-96. PubMed ID: 18640717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-Anilino-7-pyridyl-3-quinolinecarbonitriles as Src kinase inhibitors.
    Zhang N; Wu B; Boschelli DH; Golas JM; Boschelli F
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5071-4. PubMed ID: 19632113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors.
    Ashwell MA; Lapierre JM; Brassard C; Bresciano K; Bull C; Cornell-Kennon S; Eathiraj S; France DS; Hall T; Hill J; Kelleher E; Khanapurkar S; Kizer D; Koerner S; Link J; Liu Y; Makhija S; Moussa M; Namdev N; Nguyen K; Nicewonger R; Palma R; Szwaya J; Tandon M; Uppalapati U; Vensel D; Volak LP; Volckova E; Westlund N; Wu H; Yang RY; Chan TC
    J Med Chem; 2012 Jun; 55(11):5291-310. PubMed ID: 22533986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of PI3K/Akt partially leads to the inhibition of PrP(C)-induced drug resistance in gastric cancer cells.
    Liang J; Ge F; Guo C; Luo G; Wang X; Han G; Zhang D; Wang J; Li K; Pan Y; Yao L; Yin Z; Guo X; Wu K; Ding J; Fan D
    FEBS J; 2009 Feb; 276(3):685-94. PubMed ID: 19143835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the EGFR and the PKB pathway in cancer.
    Klein S; Levitzki A
    Curr Opin Cell Biol; 2009 Apr; 21(2):185-93. PubMed ID: 19216065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
    Zhu GD; Gandhi VB; Gong J; Thomas S; Woods KW; Song X; Li T; Diebold RB; Luo Y; Liu X; Guan R; Klinghofer V; Johnson EF; Bouska J; Olson A; Marsh KC; Stoll VS; Mamo M; Polakowski J; Campbell TJ; Martin RL; Gintant GA; Penning TD; Li Q; Rosenberg SH; Giranda VL
    J Med Chem; 2007 Jun; 50(13):2990-3003. PubMed ID: 17523610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.